<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607162</url>
  </required_header>
  <id_info>
    <org_study_id>RC18_0042</org_study_id>
    <nct_id>NCT03607162</nct_id>
  </id_info>
  <brief_title>Impact of a PCT(Procalcitonin) Rapid Test -Based Approach on ATB (Antibiotics) Use in Children With Fever Without Source</brief_title>
  <acronym>DIAFEVER</acronym>
  <official_title>Impact of a New Sequential Approach on Antimicrobial Use in Young Children With Fever Without Source in Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because a newly available point-of-care test may have real interest especially for children
      in the Emergency Department (ED) setting, by limiting painful and stressful venipunctures and
      decreasing the length of stay in the ED, the investigators hypothesize that integrating this
      new capillary Procalcitonin (PCT) rapid test in the DIAFEVER CPR (Clinical Prediction Rules)
      could represent a highly valuable diagnostic tool to identify a group with low Invasive
      Bacterial Infection (IBI) risk and could limit unnecessary exams and antibiotic
      prescriptions. The aim of this present study is to demonstrate the impact of this new PCT
      rapid-test-based CPR on antibiotic prescription rate in young children with Fever Without
      Source (FWS) presenting to the ED and on morbidity and mortality
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective multicentric randomized study will include 7500 febrile children aged six
      days to three years, diagnosed with fever without source, in 22 participating French and
      Swiss emergency departments, during a 12-month period.

      During one period, all children will receive usual care. In a second period, the DIAFEVER
      algorithm will be applied in half of the clusters, and in the remaining clusters, children
      will still receive usual care. At day 15 after the first consultation, data concerning death,
      intensive care unit admission, disease-specific complications, diagnosis of bacterial
      infections and proportion of antibiotic treatments will be assessed by questioning parents by
      use of an online electronic case report form or a phone call. The endpoints will be compared
      between the two groups by using a mixed logistic regression model adjusted on clustering of
      participants within centers and period within centers.

      To perform complementary studies, a biocollection will be proposed to parents when blood
      tests will be indicated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">November 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open cluster randomized before-after clinical trial with 2 parallel groups. Clusters are defined as EDs.
2 periods will be considered, one when all children will receive usual care, whatever the cluster, and a second one when, in half of the clusters, the DIAFEVER algorithm will be applied, and in the remaining clusters, children will still receive usual care.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity and mortality</measure>
    <time_frame>at day 15 after the first ED consultation</time_frame>
    <description>Related to the non-inferiority objective: Morbidity and mortality based on a binary composite outcome considering occurrence or not during the 15 days after discharge from the ED of one of the following events:
death
intensive care unit admission for any reason
disease-specific complications (ie, cerebral damage with neurologic impairment, deathless, blindness amputation, cutaneous necrosis requiring surgery, definitive renal failure etc.)
diagnosis of Invasive Bacterial Infection or Serious Bacterial Infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in antibiotics exposure</measure>
    <time_frame>at day 15 after the first ED consultation</time_frame>
    <description>Related to the superiority objective : change in antibiotics exposure based on the proportion of children who received ABT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the current epidemiology of FWS among children &lt; 36 months old admitted in an ED</measure>
    <time_frame>At inclusion visit</time_frame>
    <description>The incidence of FWS among children admitted in EDs, the incidence of Severe Bacterial Infection (SBI) and IBI among the children admitted in the ED with FWS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic value of the DIAFEVER prediction rule for SBI and IBI diagnosis</measure>
    <time_frame>At inclusion visit</time_frame>
    <description>Assessment of sensitivity, specificity, predictive values, Likelihood Ratio, of the DIAFEVER prediction rule (combining high- and intermediate-risk versus low-risk populations) considering the SBI/IBI diagnosis as the gold standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the DIAFEVER prediction rule on median length of stay in the ED</measure>
    <time_frame>at day 15 after the first ED consultation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the DIAFEVER prediction rule on the proportion of children with laboratory tests prescription</measure>
    <time_frame>at day 15 after the first ED consultation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the DIAFEVER prediction rule on hospitalization rates</measure>
    <time_frame>at day 15 after the first ED consultation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vaccine coverage of children consulting for FWS evaluated by the vaccination coverage rate (among children with FWS)</measure>
    <time_frame>at day 15 after the first ED consultation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>theoretically vaccine-preventable SBI</measure>
    <time_frame>at day 15 after the first ED consultation</time_frame>
    <description>theoretically vaccine-preventable SBI is defined as an infection with an identified serotype included in the national vaccine schedule and occurring in a child with untimely vaccination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7290</enrollment>
  <condition>Fever Without Source</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Local usual management of FWS (pragmatic approach)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DIAFEVER algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New DIAFEVER sequential algorithm PCT rapid test-based will be applied</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DIAFEVER algorithm</intervention_name>
    <description>PCT rapid test-based predictive algorithm</description>
    <arm_group_label>DIAFEVER algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Febrile children aged 6 days to &lt;36 months old presenting to an ED at their initial
             visit with an acute illness for a maximum of 8 days and diagnosed with a FWS defined
             as body temperature (measured at home or the ED) &gt; 38°C and a physical examination by
             a physician without source

          -  Oral non-opposition will be requested from one of the parents or caregivers of the
             patient.

          -  No current antibiotic treatment or within the 48 hours before the ED presentation.

          -  Parental affiliation with an appropriate health insurance system

          -  Parents speaking French

        Exclusion Criteria:

          -  A clear source of fever identified after a careful inspection of medical history and a
             physical examination

          -  No fever on consultation or previously subjectively assessed by parents without use of
             a thermometer

          -  Refusal of the parents to participate

          -  Child ≥ 36 months or &lt; 6 days old (ie, early-onset neonatal infection)

          -  Ongoing ABT treatment or within the 48 hours before ED presentation

          -  Children with FWS who revisited the ED after their initial visit

          -  Participation with another interventional study involving human subjects or being in
             the exclusion period at the end of a previous study involving human subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christele Gras-Le Guen, Pr</last_name>
    <phone>+33240087671</phone>
    <email>christele.grasleguen@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne DROUARD</last_name>
    <email>anne.drouard@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle DARVIOT</last_name>
    </contact>
    <investigator>
      <last_name>Estelle DARVIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion LEROUGE-BAILHACHE</last_name>
    </contact>
    <investigator>
      <last_name>Marion LEROUGE-BAILHACHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lydie ABALEA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe ECKART</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent GAJDOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthieu VERDAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Romain BASMACI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandra BISCARDI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine BARBIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas BLANCHAIS</last_name>
    </contact>
    <investigator>
      <last_name>Thomas BLANCHAIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional University Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François DUBOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Antoine Saint Vincent Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie MOUKAGNI-PELZER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Bretagne Hospital</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>cédric MENAGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves GILLET</last_name>
    </contact>
    <investigator>
      <last_name>Yves GILLET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gael GUYON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional University Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amélie GATIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hervé HAAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François ANGOULVANT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luigi TITOMANLIO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tiphaine HERVE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu COME</last_name>
    </contact>
    <investigator>
      <last_name>Matthieu COME</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Brieuc Hospital</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent CHEVRET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aymeric CANTAIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nora DEETJEN-RADULESCU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Camille BREHIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain GERVAIX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacteriemia</keyword>
  <keyword>meningitis</keyword>
  <keyword>Urinary tract infection</keyword>
  <keyword>antibiotic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

